Publications by authors named "Bernadette V Marquez-Nostra"
Article Synopsis
- Gliomas have varied molecular profiles that can impact patient survival and treatment choices, but existing diagnostic methods are often invasive and complex due to tumor heterogeneity.
- A systematic review analyzed various machine learning algorithms predicting glioma molecular subtypes based on MRI data, screening thousands of studies to find 85 relevant articles.
- Despite promising accuracy rates in internal validations (up to 88% for IDH mutation status), the review noted significant bias and limitations due to a lack of external validation and incomplete data across studies.
The success of human epidermal growth factor receptor 2 (HER2)-targeted therapy depends on accurate characterization of HER2 expression, but current methods available have several limitations. This study aims to investigate the feasibility of [Zr]pertuzumab imaging to monitor early response to Ado-trastuzumab emtansine (T-DM1) therapy in mice bearing xenografts of HER2-positive breast cancer (BCa). Pertuzumab was conjugated to DFO-Bz-NCS and labeled with Zr.
View Article and Find Full Text PDFPurpose: To evaluate whether tumor uptake of [Zr]trastuzumab can distinguish HER2-positive from HER2-negative breast cancer.
Methods: Women with HER2-positive (n = 34) and HER2-negative (n = 16) breast cancer underwent PET/CT 5 ± 2 days following [Zr]trastuzumab administration. HER2 status was determined based on immunohistochemistry and/or fluorescence in situ hybridization of primary or metastatic/recurrent tumor.
Since its discovery, the human epidermal growth factor 2 (HER2) has been extensively studied. Presently, there are 2 standard diagnostic techniques to assess HER2 status in biopsies: immunohistochemistry and fluorescence in situ hybridization. While these techniques have played an important role in the treatment of patients with HER2-positive cancer, they both require invasive biopsies for analysis.
View Article and Find Full Text PDFRadioimmunotherapies with monoclonal antibodies to the B-lymphocyte antigen 20 (CD20) are effective treatments for B-cell lymphomas, but U.S. Food and Drug Administration-approved radioimmunotherapies exclusively use radiolabeled murine antibodies, potentially limiting redosing.
View Article and Find Full Text PDFHigh levels of expression of glycoprotein non-metastatic B (gpNMB) in triple negative breast cancer (TNBC) and its association with metastasis and recurrence make it an attractive target for therapy with the antibody drug conjugate, glembatumumab vedotin (CDX-011). This report describes the development of a companion PET-based diagnostic imaging agent using Zr-labeled glembatumumab ([Zr]DFO-CR011) to potentially aid in the selection of patients most likely to respond to targeted treatment with CDX-011. [Zr]DFO-CR011 was characterized for its pharmacologic properties in TNBC cell lines.
View Article and Find Full Text PDFPurpose: The purpose of the present study is to evaluate safety, human radiation dosimetry, and optimal imaging time of [Zr]trastuzumab in patients with HER2-positive breast cancer.
Procedures: Twelve women with HER2-positive breast cancer underwent [Zr]trastuzumab positron emission tomography (PET)/X-ray computed tomography (CT) twice within 7 days post-injection. Biodistribution data from whole-torso PET/CT images and organ time-activity curves were created using data from all patients.